Description

Poly(allylamine)

Poly(allylamine) is a pharmaceutical-grade, cationic polymer used primarily for its film-forming, binding, complexation, and controlled-release capabilities in advanced drug delivery systems, biomedical applications, and nanomedicine platforms. Its high amine content provides unique ionic interactions, making it valuable for mucoadhesive delivery, gene delivery, and complexation with polyanionic compounds.

• High-purity, pharmaceutical-grade cationic polymer
• Strong ionic binding capacity for polyelectrolyte complexation and API stabilization
• Supports mucoadhesive, controlled-release, and targeted delivery systems
• Biocompatible and tunable for oral, mucosal, and parenteral formulations

Poly(allylamine) contains primary amine groups along its polymer backbone, enabling ionic interactions with negatively charged molecules, including nucleic acids, proteins, and certain small-molecule APIs. This ionic behavior allows it to serve as a carrier for gene delivery, controlled-release oral tablets, and mucoadhesive delivery platforms targeting localized or systemic absorption.

In drug delivery, Poly(allylamine) is used to create polyelectrolyte complexes, protective nanocarriers, or ionic crosslinked matrices. In gene therapy, its cationic profile allows complexation with DNA or RNA, facilitating cellular uptake and transfection. Its mucoadhesive properties support enhanced retention in buccal, nasal, and gastrointestinal formulations.

Pharmaceutical developers and researchers seeking to purchase Poly(allylamine) benefit from CarboMer ’s consistent manufacturing processes, traceability, and regulatory support for advanced formulation development and global registration.

The product is supplied in tamper-evident, moisture-controlled packaging to preserve stability during storage and transport. Minimum order quantities (MOQ), lead times, and full regulatory support packages are available to support clinical and commercial development.

Each production batch undergoes validated analytical testing for molecular weight distribution, amine content, residual monomers, heavy metals, endotoxins, and microbial limits to ensure consistency and regulatory compliance.

As with all CarboMer  excipients and advanced delivery polymers, Poly(allylamine) is fully supported by technical consultation, formulation guidance, and regulatory expertise to accelerate pharmaceutical development from early-stage research to commercial-scale production.